Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 48,465 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Homocystinuria
Interventions: Pegtibatinase, Placebo; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more

Conditions: NAFLD
Interventions: Dietary intervention with very low calorie diet (VLCD), Control Arm; Dietary Supplement · Other
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Healthy
Interventions: Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Insomnia, Depression
Interventions: Digital Insomnia Program, Digital Mental Health Program, Psychoeducation; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Depression - Major Depressive Disorder, Insomnia
Interventions: Alpha phase-locked auditory stimulation, Sham Stimulation; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 20 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Low Back Pain
Interventions: identify L4/L5; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Treatment-resistant Schizophrenia
Interventions: Lu AF35700, Risperidone, Olanzapine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 10
States / cities: San Diego, California • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Snake Bite, Blood Coagulation Disorders
Interventions: Anavip, CroFab; Biological
Lead sponsor: Instituto Bioclon S.A. de C.V.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Cutaneous Melanoma
Interventions: Atezolizumab; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms
Interventions: GSK3901961, GSK3845097, GSK4427296, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 9
States / cities: Jacksonville, Florida • Atlanta, Georgia • Westwood, Kansas + 5 more

Conditions: Acute Mountain Sickness
Interventions: Prochlorperazine Maleate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Evergreen, Colorado

Conditions: Myelofibrosis (MF)
Interventions: Placebo for Navitoclax, Ruxolitinib, Navitoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 35
States / cities: Springdale, Arkansas • Fullerton, California • La Jolla, California + 29 more

Conditions: Hypotension
Interventions: Phenylephrine, Norepinephrine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma, Mesothelioma, Sarcoma, Non Hodgkin Lymphoma, B Cell Lymphoma, Epithelioid Sarcoma
Interventions: APG-5918; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Springdale, Arkansas

Conditions: HIV
Interventions: Incentives for Viral Suppression, Standard HIV Medical Care; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Craniocerebral Trauma, Stroke, Intracranial Hemorrhages
Interventions: Early cranioplasty, Standard-of-care cranioplasty; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sickle Cell Disease
Interventions: SMART app; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes
Interventions: Culturally tailored HLWD; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: MCI, Subjective Cognitive Decline (SCD), Mild Behavioral Impairment
Interventions: Cognitive Remediation, Cognitive Remediation II; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 60 Years to 89 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Obsessive Compulsive Disorder
Interventions: Medtronic Percept Deep Brain Stimulation; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Charlestown, Massachusetts • Minneapolis, Minnesota

Conditions: Penile Diseases
Interventions: RestoreX PTT - randomized and open label, RestoreX PTT - open label phase only; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Dementia
Interventions: QEEG-based Neurofeedback Training; Behavioral
Lead sponsor: Quietmind Foundation; Other
Eligibility: 45 Years to 85 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Lafayette Hill, Pennsylvania

Conditions: Sarcoma
Interventions: cilengitide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 3
States / cities: La Jolla, California • San Francisco, California • Nashville, Tennessee

Search by objective public record fields.

Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

Evaluating the Impact of Digital Behavioral Interventions to Address Insomnia and Depression in Breast Cancer Survivors Using an Adaptive Design

Auditory Stimulation for Insomnia and Depression

Accuro Versus Traditional Landmark Palpation Technique to Determine Accurate Spinal Level for Procedures

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

Vasopressor Outcomes in Spine Surgery

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Suppression of HIV 1 RNA in People Living With HIV

Timing Impact of Early vs. Late Cranioplasty on Hemicraniectomy Outcomes

SMART Mobile Application Technology Utilization in the Treatment of Sickle Cell Disease Post Day Hospital Discharge

Healthy Living for You

FACE Phase II (a Stage II Trial)

Combined Cortical/Subcortical Recording and Stimulation as a Circuit-Oriented Treatment for Obsessive-Compulsive Disorder

Efficacy of Penile Traction Therapy Using a Novel Device

Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy

EEG Biofeedback to Improve Memory in Adults With Dementia

EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma